KR101834024B1 - 치환된 베타―시클로덱스트린에 의해 안정화된 포사코나졸 정맥내 용액 제제 - Google Patents

치환된 베타―시클로덱스트린에 의해 안정화된 포사코나졸 정맥내 용액 제제 Download PDF

Info

Publication number
KR101834024B1
KR101834024B1 KR1020127034087A KR20127034087A KR101834024B1 KR 101834024 B1 KR101834024 B1 KR 101834024B1 KR 1020127034087 A KR1020127034087 A KR 1020127034087A KR 20127034087 A KR20127034087 A KR 20127034087A KR 101834024 B1 KR101834024 B1 KR 101834024B1
Authority
KR
South Korea
Prior art keywords
posaconazole
pharmaceutical composition
cyclodextrin
solution
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127034087A
Other languages
English (en)
Korean (ko)
Other versions
KR20130114603A (ko
Inventor
수잔 케이. 헤임베처
데이비드 몬테이스
제임스 디. 핍킨
Original Assignee
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101834024(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 머크 샤프 앤드 돔 코포레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20130114603A publication Critical patent/KR20130114603A/ko
Application granted granted Critical
Publication of KR101834024B1 publication Critical patent/KR101834024B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127034087A 2010-06-29 2011-06-24 치환된 베타―시클로덱스트린에 의해 안정화된 포사코나졸 정맥내 용액 제제 Active KR101834024B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35970110P 2010-06-29 2010-06-29
US61/359,701 2010-06-29
PCT/US2011/041715 WO2012005973A1 (en) 2010-06-29 2011-06-24 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin

Publications (2)

Publication Number Publication Date
KR20130114603A KR20130114603A (ko) 2013-10-17
KR101834024B1 true KR101834024B1 (ko) 2018-03-02

Family

ID=45441500

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127034087A Active KR101834024B1 (ko) 2010-06-29 2011-06-24 치환된 베타―시클로덱스트린에 의해 안정화된 포사코나졸 정맥내 용액 제제

Country Status (20)

Country Link
US (2) US9023790B2 (enExample)
EP (3) EP2588116A4 (enExample)
JP (1) JP6008849B2 (enExample)
KR (1) KR101834024B1 (enExample)
CN (2) CN107049935A (enExample)
AU (1) AU2011276680B2 (enExample)
BR (1) BR112012033077B8 (enExample)
CA (1) CA2802929C (enExample)
CY (1) CY1124690T1 (enExample)
DK (1) DK3391890T3 (enExample)
ES (1) ES2893444T3 (enExample)
HR (1) HRP20211686T1 (enExample)
HU (1) HUE056581T2 (enExample)
LT (1) LT3391890T (enExample)
MX (2) MX338685B (enExample)
PL (1) PL3391890T3 (enExample)
PT (1) PT3391890T (enExample)
RS (1) RS62583B1 (enExample)
SI (1) SI3391890T1 (enExample)
WO (1) WO2012005973A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
PL3391890T3 (pl) 2010-06-29 2021-12-20 Merck Sharp & Dohme Corp. Preparaty dożylnego roztworu pozakonazolu stabilizowane podstawioną beta-cyklodekstryną
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
EP3052487B1 (en) 2013-10-03 2018-09-05 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
CN104546724A (zh) * 2013-10-12 2015-04-29 博瑞生物医药技术(苏州)有限公司 一种抗真菌药的固体分散体
CA2931144C (en) 2013-11-22 2020-02-04 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
CN105879041A (zh) * 2014-11-14 2016-08-24 北京赛林泰医药技术有限公司 一种泊沙康唑口服液及其制备方法
EP3220954A4 (en) * 2014-11-19 2018-06-27 Gufic Biosciences Limited Process for preparation of parenteral formulation of anidulafungin
CN104473871B (zh) * 2014-11-28 2017-03-08 济南康和医药科技有限公司 一种泊沙康唑脂肪乳注射液及其制备方法
CN106265534A (zh) * 2015-05-25 2017-01-04 江苏正大丰海制药有限公司 一种泊沙康唑冻干粉针剂的制备方法
CN106511262A (zh) * 2015-09-11 2017-03-22 上海美悦生物科技发展有限公司 一种泊沙康唑口服溶液剂及其制备方法
US10517867B2 (en) 2016-02-04 2019-12-31 Wuhan Ll Science And Technology Development Co., Ltd. Posaconazole derivative, pharmaceutical composition and use thereof
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途
CN111989121B (zh) 2018-04-16 2024-08-13 默克专利股份有限公司 高浓缩蛋白质制剂的粘度降低
CN110711174A (zh) * 2018-07-11 2020-01-21 郑州泰丰制药有限公司 一种泊沙康唑注射液中间体溶液配制方法
TR201820816A2 (tr) * 2018-12-28 2020-07-21 Polifarma Ilac Sanayi Ve Ticaret Anonim Sirketi Si̇klodekstri̇n ve şeker i̇çeren stabi̇l enjekte edi̇lebi̇li̇r posakonazol formülasyonlari
EP4161515A4 (en) * 2020-06-06 2024-08-07 Invengene Limited STABLE LIQUID COMPOSITIONS OF POSACONAZOLE
CN115429748A (zh) * 2021-06-02 2022-12-06 江苏奥赛康药业有限公司 一种泊沙康唑注射液的制备方法
WO2023148763A1 (en) * 2022-02-01 2023-08-10 Cipla Limited Injectable pharmaceutical compositions of azole antifungal agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117831A1 (en) * 2004-05-28 2005-12-15 Schering Corporation Injectable pharmaceutical suspension comprising posaconazole
US20090270348A1 (en) * 2008-04-28 2009-10-29 Antle Vincent Sulfoalkyl Ether Cyclodextrin Compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5257985A (en) 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
AU681753B2 (en) 1993-12-21 1997-09-04 Merck Sharp & Dohme Corp. Tetrahydrofuran antifungals
US5703079A (en) 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
US5661151A (en) 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
US6713481B1 (en) 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
DK1499274T3 (da) 2002-04-30 2010-02-08 Otsuka Pharma Co Ltd Medicinalbeholder med flere kamre og pose til at omslutte samme
CA2528493C (en) * 2003-06-06 2009-01-20 Sankyo Company Limited Medicinal composition containing triazole compound
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
US20060160823A1 (en) 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
RU2394573C2 (ru) * 2004-08-13 2010-07-20 Шеринг-Плоу Лтд. Фармацевтическая композиция
WO2006098345A1 (ja) * 2005-03-15 2006-09-21 Ajinomoto Co., Inc. 薬剤移送具
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN101442987A (zh) * 2005-12-14 2009-05-27 扎尔斯制药公司 喷雾制剂和皮肤给药方法
BRPI0712130A2 (pt) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd formulações de posaconazol em nanopartìculas
DK2061458T3 (en) * 2006-09-15 2015-03-09 Univ Minnesota Topiramate compositions and methods for their use
JP2010515762A (ja) 2007-01-16 2010-05-13 エンゾン ファーマスーティカルズ インコーポレイテッド ポサコナゾール−ポリマー複合体、並びに、ポサコナゾールおよびそのポリマー複合体を使用した治療方法
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
JP2011529072A (ja) * 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
PL3391890T3 (pl) 2010-06-29 2021-12-20 Merck Sharp & Dohme Corp. Preparaty dożylnego roztworu pozakonazolu stabilizowane podstawioną beta-cyklodekstryną

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117831A1 (en) * 2004-05-28 2005-12-15 Schering Corporation Injectable pharmaceutical suspension comprising posaconazole
US20090270348A1 (en) * 2008-04-28 2009-10-29 Antle Vincent Sulfoalkyl Ether Cyclodextrin Compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMIN A. NOMEIR et al, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2000, 727-731*

Also Published As

Publication number Publication date
LT3391890T (lt) 2021-11-10
US9023790B2 (en) 2015-05-05
AU2011276680A1 (en) 2012-12-06
JP2013535422A (ja) 2013-09-12
MX338685B (es) 2016-04-26
PT3391890T (pt) 2021-10-14
US9358297B2 (en) 2016-06-07
US20130096053A1 (en) 2013-04-18
KR20130114603A (ko) 2013-10-17
BR112012033077A2 (pt) 2016-11-22
WO2012005973A1 (en) 2012-01-12
CA2802929C (en) 2019-01-08
HRP20211686T1 (hr) 2022-03-04
US20150265715A1 (en) 2015-09-24
EP2588116A1 (en) 2013-05-08
SI3391890T1 (sl) 2021-11-30
RS62583B1 (sr) 2021-12-31
BR112012033077B1 (pt) 2020-01-21
CY1124690T1 (el) 2022-07-22
EP3960185A1 (en) 2022-03-02
BR112012033077B8 (pt) 2023-04-25
RU2013103724A (ru) 2014-08-10
AU2011276680B2 (en) 2014-07-17
ES2893444T3 (es) 2022-02-09
HUE056581T2 (hu) 2022-02-28
JP6008849B2 (ja) 2016-10-19
MX346901B (es) 2017-04-04
EP3391890B1 (en) 2021-08-25
CA2802929A1 (en) 2012-01-12
CN107049935A (zh) 2017-08-18
EP2588116A4 (en) 2013-12-04
MX2012015168A (es) 2013-01-24
DK3391890T3 (da) 2021-11-01
PL3391890T3 (pl) 2021-12-20
CN102958528A (zh) 2013-03-06
EP3391890A1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
KR101834024B1 (ko) 치환된 베타―시클로덱스트린에 의해 안정화된 포사코나졸 정맥내 용액 제제
EP2785352B1 (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
US11819533B2 (en) Compositions and methods for the treatment of fungal infections
US20120142768A1 (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
CN107810000B (zh) 来氟米林的可注射药物组合物
AU2018341136A1 (en) Parenteral formulation comprising siponimod
RU2575768C2 (ru) Составы внутривенных растворов позаконазола, стабилизированные посредством замещенного бета-циклодекстрина
US20040072797A1 (en) Storage stable eplerenone formulation
US20240238275A1 (en) Hydromorphone formulations for multi-dose products
CN101677943A (zh) 使用苯甲醇的多剂量浓缩艾司洛尔
WO2016079749A2 (en) Process for preparation of parenteral formulation of anidulafungin
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170111

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170730

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170111

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170730

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170313

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160321

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20171123

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20171027

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170730

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170313

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160321

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20201224

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 8

End annual number: 8